Search Result

Results for "

radiotherapy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (1) Aurora Kinase (1) Autophagy (1) BCRP (1) Biochemical Assay Reagents (5) Caspase (1) Dihydropyrimidine Dehydrogenase (DPD) (1) DNA-PK (5) DNA/RNA Synthesis (1) EGFR (2) ERK (1) FAP (1) FOXO (1) Influenza Virus (1) Interleukin Related (1) MMP (2) Necroptosis (1) NEKs (1) NF-κB (1) p38 MAPK (1) PI3K (2) PSMA (2) Pyroptosis (1) Radionuclide-Drug Conjugates (RDCs) (1) Raf (1) Reactive Oxygen Species (ROS) (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) YTHDF (1)
By Research Areas:	Cancer (19) Cardiovascular Disease (1) Endocrinology (1) Infection (1) Inflammation/Immunology (6)

By Targets:

Akt (1)

Apoptosis (1)

Aurora Kinase (1)

Autophagy (1)

BCRP (1)

Biochemical Assay Reagents (5)

Caspase (1)

Dihydropyrimidine Dehydrogenase (DPD) (1)

DNA-PK (5)

DNA/RNA Synthesis (1)

EGFR (2)

ERK (1)

FAP (1)

FOXO (1)

Influenza Virus (1)

Interleukin Related (1)

MMP (2)

Necroptosis (1)

NEKs (1)

NF-κB (1)

p38 MAPK (1)

PI3K (2)

PSMA (2)

Pyroptosis (1)

Radionuclide-Drug Conjugates (RDCs) (1)

Raf (1)

Reactive Oxygen Species (ROS) (1)

TNF Receptor (1)

Toll-like Receptor (TLR) (1)

YTHDF (1)

By Research Areas:

Cancer (19)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (6)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-154919

DC-Y13-27 4 Publications Verification	YTHDF FOXO MMP Pyroptosis Interleukin Related	Endocrinology Cancer
DC-Y13-27 is a DC-Y13 derivative and YTHDF2 inhibitor (K_D: 37.9 μM). DC-Y13-27 inhibits YTHDF2, restores FOXO3 and TIMP1 protein levels, and reduces MMP1/3/7/9 expression. DC-Y13-27 induces Pyroptosis and increases IL-1β secretion. DC-Y13-27 reduces intervertebral disc degeneration and enhances the response to radiotherapy in colon cancer and melanoma. DC-Y13-27 has antitumor activity against breast cancer .

HY-114923

SU-11752	DNA-PK PI3K	Cancer
SU-11752 is an inhibitor for DNA-dependent protein kinase (DNA-PK) with an IC₅₀ of 0.13 μM. SU-11752 inhibits PI3K p110γ kinase with IC₅₀ of 1.1 μM. SU-11752 binds competitively for ATP-site in DNA-PK, results in inhibition of intracellular DNA double-strand break repair and increases the sensitivity of cells to radiotherapy .

HY-134181A

Tremella polysaccharide, MW<1000000, cosmetic grade	Biochemical Assay Reagents	Inflammation/Immunology
Tremella polysaccharide, MW<1000000, cosmetic grade, one of the fungus polysaccharides, possesses immunity enhancing capabilities. Polysaccharidase has the potential for leukopenia induced by chemotherapy and radiotherapy research .

HY-134181

Tremella polysaccharide, MW>1000000, cosmetic grade	Biochemical Assay Reagents	Inflammation/Immunology
Tremella polysaccharide, MW>1000000, cosmetic grade, one of the fungus polysaccharides, possesses immunity enhancing capabilities. Polysaccharidase has the potential for leukopenia induced by chemotherapy and radiotherapy research .

HY-171561

DOTAM-Maleimide triTFA	Biochemical Assay Reagents	Others
DOTAM-Maleimide triTFA is a bifunctional chelator, combining the DOTAM structure with a maleimide group for efficient thiol coupling. DOTAM-Maleimide triTFA forms stable complexes with radiometals, promising for applications in molecular imaging and radiotherapy .

HY-144036

DNA-PK-IN-3	DNA-PK	Cancer
DNA-PK-IN-3 is a potent inhibitor of DNA-PK. DNA-PK-IN-3 synergistically enhances the effect of radiotherapy and chemotherapy and effectively inhibits tumor growth. DNA-PK-IN-3 also effectively reduces the damage to normal cells and reducing side effects. DNA-PK-IN-3 has the potential for the research of cancer disease (extracted from patent WO2021213460A1, compound 4) .

HY-144038

DNA-PK-IN-5	DNA-PK	Cancer
DNA-PK-IN-5 is a potent inhibitor of DNA-PK. DNA-PK-IN-5 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-5 enhances the sensitivity of tumor tissues to radiotherapy, overcomes the problem of agent resistance, and enhances the inhibitory effect on a variety of solid tumors and hematological tumors (extracted from patent WO2021204111A1, compound 2) .

HY-144039

DNA-PK-IN-6	DNA-PK	Cancer
DNA-PK-IN-6 is a potent inhibitor of DNA-PK. DNA-PK-IN-6 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-6 enhances the sensitivity of tumor tissues to radiotherapy, overcomes the problem of agent resistance, and enhances the inhibitory effect on a variety of solid tumors and hematological tumors (extracted from patent WO2021197159A1, compound 6) .

HY-172137

FAPI-FUSCC-07	FAP	Cancer
FAPI-FUSCC-07 is a targeted probe for fibroblast activation protein (FAP), exhibiting high affinity binding to FAP for applications in molecular imaging, tumor diagnosis, and radiotherapy .

HY-121496

3M-011	Toll-like Receptor (TLR) Influenza Virus	Infection Inflammation/Immunology Cancer
3M-011 is a potent dual toll-like receptor TLR7/8 agonist and a cytokine inducer. 3M-011 significantly inhibits H3N2 influenza viral replication in the nasal cavity. 3M-011 is also a potent adjuvant to radiotherapy that induces local and profound systemic immune responses during radiotherapy. 3M-011 strongly has antitumor action .

HY-123733A

MIP-1095 TFA RPS-001 TFA	PSMA	Cancer
MIP-1095 (RPS-001) TFA is a potent inhibitor of PSMA with good biodistribution and efficient targeting of tumor lesions. In applications, MIP-1095 TFA will be isotopically labeled ( ¹³¹I labeled) as an imaging probe to indicate tumor progression. And ¹³¹I-MIP-1095 showed higher renal uptake in mice .

HY-144425

BSc5367	NEKs	Inflammation/Immunology
BSc5367 is a potent Nek1 inhibitor with an IC₅₀ of 11.5 nM. NIMA-related protein kinase Nek1 is crucially involved in cell cycle regulation, DNA repair and microtubule regulation and dysfunctions of Nek1 play key roles in amyotrophic lateral sclerosis (ALS), polycystic kidney disease (PKD) and several types of radiotherapy resistant cancer .

HY-17469

Gimeracil 2 Publications Verification Gimestat	DNA/RNA Synthesis Dihydropyrimidine Dehydrogenase (DPD)	Cancer
Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .

HY-119307

Apratastat 2 Publications Verification TMI-005	MMP TNF Receptor	Cancer
Apratastat (TMI-005) is an orally active, non-selective and reversible TACE/MMPs inhibitor, can inhibit inhibit the release of TNF-α. Apratastat has the potential to overcome radiotherapy-resistance in non-small cell lung cancer (NSCLC) . Apratastat is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10251

BMS-599626 AC480	EGFR	Cancer
BMS-599626 (AC480) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC₅₀s of 20 and 30 nM, respectively. BMS-599626 displays ~8-fold less potent to HER4 (IC₅₀=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy .

HY-101570

Nedisertib Maximum Cited Publications 20 Publications Verification Peposertib; M3814	DNA-PK BCRP	Cancer
Nedisertib (Peposertib) is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC₅₀ value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity .

HY-10180A

MLN8054 sodium	Aurora Kinase	Cancer
MLN8054 sodium is an Aurora A inhibitor with radiosensitivity-enhancing activity. MLN8054 sodium can activate the DNA double-strand break reaction of prostate cancer cells in in vitro experiments. The application of MLN8054 sodium is closely related to accumulation in the G2/M phase of the cell cycle and polyploid formation. In vivo experiments show that MLN8054 sodium can significantly delay the growth of prostate cancer tumors and promote tumor cell apoptosis when used in combination with radiotherapy .

HY-163683

EB-PSMA-617	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy. In preclinical studies using PC3-PIP-loaded mice, EB-PSMA-617 demonstrated prolonged blood half-life, increased accumulation in PSMA-positive tumors, and successful tumor elimination with lower radioactivity .

HY-12010

BMS-599626 Hydrochloride 3 Publications Verification AC480 Hydrochloride	EGFR	Cancer
BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC₅₀s of 20 and 30 nM, respectively. BMS-599626 Hydrochloride displays ~8-fold less potent to HER4 (IC₅₀=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 Hydrochloride inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy .

HY-111940

LUT014	Raf p38 MAPK ERK	Inflammation/Immunology
LUT014 is a topical inhibitor targeting BRAF that cannot pass through the blood-brain barrier. LUT014 inhibits BRAF kinase and abnormally activates the MAPK/ERK signaling pathway, promoting the proliferation of epidermal keratinocytes, repairing skin barrier damage caused by radiation damage, and alleviating inflammatory responses. LUT014 is independent of RAS signaling and accelerates the repair and regeneration of damaged skin cells. LUT014 can be used to study radiation dermatitis, especially skin damage caused by breast cancer radiotherapy .

HY-19416

AEOL-10150 pentachloride 1 Publications Verification	Reactive Oxygen Species (ROS) NF-κB	Inflammation/Immunology Cancer
AEOL-10150 pentachloride is a metalloporphyrin-catalyzed antioxidant and a superoxide dismutase mimetic. AEOL-10150 pentachloride scavenges ROS and RNS, and modulates the NF-κB signaling pathway. AEOL-10150 pentachloride has potent antioxidant and anti-inflammatory activities. AEOL-10150 pentachloride effectively mitigates tissue damage caused by radiation and chemical agents such as CEES (HY-W199190). AEOL-10150 pentachloride synergizes with radiotherapy to exert anticancer effects on prostate tumors .

HY-131326

DOTA-tris(tBu)ester NHS ester	Biochemical Assay Reagents	Cancer
DOTA-tris(tBu)ester NHS ester is a DOTA-based chelator. DOTA-tris(tBu)ester NHS ester can efficiently chelate a variety of metal ions to form stable complexes suitable for cancer diagnosis, treatment and molecular imaging. DOTA-tris(tBu)ester NHS ester can significantly increase the loading capacity of metal ions through polymerization reaction, thereby enhancing the specific activity of imaging signals or radiotherapy. NHS ester can be used to label primary amines (R-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules .

HY-164388

Z-VAD 4 Publications Verification	Caspase Apoptosis Autophagy Necroptosis	Cardiovascular Disease Cancer
Z-VAD is an irreversible, broad-spectrum pan-caspase inhibitor that can inhibit a variety of caspases including caspase-3, -6, -7, -8, -9, etc. (with a weaker inhibitory effect on caspase-2). Z-VAD can block apoptosis signaling pathways, induce autophagy and necrosis in tumor cells, and has anti-angiogenic activity. Z-VAD can enhance the sensitivity of breast cancer and lung cancer cells to radiotherapy in vitro and in vivo, and prolong the growth delay of tumor xenograft models. Z-VAD is well tolerated and is mainly used in research related to cancer radiosensitization and cell death pathway regulation .

HY-116604

RLX PD 139530	PI3K Akt	Cancer
RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness. RLX highlights the necessity for further research into the tumor microenvironment’s dynamics to develop more tailored treatment approaches for diverse tumor types.

HY-P3566

(D-Lys16)-ACTH (1-24) (human, bovine, mouse, ovine, porcine, rabbit, rat)	Biochemical Assay Reagents	Others
(D-Lys16)-ACTH (1-24) (human, bovine, mouse, ovine, porcine, rabbit, rat) is the reaction product with gadolinium tetraazacyclododecanetriacetate derivative. (D-Lys16)-ACTH (1-24) (human, bovine, mouse, ovine, porcine, rabbit, rat) involves in preparation of tetraazacyclododecane macrocycle metal complexes for production of conjugates with biomolecules and for use as NMR contrast agents, radiodiagnostic agents and for radioresearch .

Cat. No.	Product Name

HY-L179

Radiosensitizer Library	40 compounds
Radiotherapy is a common treatment for various cancers, and more than 50% of cancer patients require radiotherapy during the disease treatment. With advances in radiation technology and a better understanding of tumor biology, the efficacy of radiation therapy has gradually improved, and more and more patients have benefited from it. However, even with the use of advanced radiotherapy techniques, there are still many malignant tumor cells with low sensitivity to radiation, leading to the radiation effect is not ideal. To solve this problem, radiosensitizers have received more and more attention. Radiosensitizer is a kind of drug that can enhance the radiosensitivity of tumor cells and improve the effect of radiotherapy. Radiation sensitizers act in a variety of ways, such as killing hypoxic cells, enhancing DNA damage, inhibiting DNA damage repair, and blocking cell cycle progression, making tumor cells more susceptible to radiation damage and death than surrounding normal cells. MCE designs a unique collection of 40 compounds with definite reported radiosensitization. It can be used for drug combination research in anti-cancer treatment.

Radiosensitizer Library

40 compounds

Radiotherapy is a common treatment for various cancers, and more than 50% of cancer patients require radiotherapy during the disease treatment. With advances in radiation technology and a better understanding of tumor biology, the efficacy of radiation therapy has gradually improved, and more and more patients have benefited from it. However, even with the use of advanced radiotherapy techniques, there are still many malignant tumor cells with low sensitivity to radiation, leading to the radiation effect is not ideal. To solve this problem, radiosensitizers have received more and more attention. Radiosensitizer is a kind of drug that can enhance the radiosensitivity of tumor cells and improve the effect of radiotherapy. Radiation sensitizers act in a variety of ways, such as killing hypoxic cells, enhancing DNA damage, inhibiting DNA damage repair, and blocking cell cycle progression, making tumor cells more susceptible to radiation damage and death than surrounding normal cells.

MCE designs a unique collection of 40 compounds with definite reported radiosensitization. It can be used for drug combination research in anti-cancer treatment.

HY-L171

Anti-Hematopathy Compound Library	3,424 compounds
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 3,424 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Anti-Hematopathy Compound Library

3,424 compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 3,424 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

HY-L135

Cancer Stem Cells Compound Library	2,738 compounds
With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on. Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment. MCE supplies a unique collection of 2,738 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.

Cancer Stem Cells Compound Library

2,738 compounds

With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on.

Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment.

MCE supplies a unique collection of 2,738 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.

HY-L074

Anti-Breast Cancer Compound Library	2,559 compounds
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 2,559 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Anti-Breast Cancer Compound Library

2,559 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,559 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Type

HY-134181A

Tremella polysaccharide, MW<1000000, cosmetic grade	Carbohydrates
Tremella polysaccharide, MW<1000000, cosmetic grade, one of the fungus polysaccharides, possesses immunity enhancing capabilities. Polysaccharidase has the potential for leukopenia induced by chemotherapy and radiotherapy research .

HY-134181

Tremella polysaccharide, MW>1000000, cosmetic grade	Carbohydrates
Tremella polysaccharide, MW>1000000, cosmetic grade, one of the fungus polysaccharides, possesses immunity enhancing capabilities. Polysaccharidase has the potential for leukopenia induced by chemotherapy and radiotherapy research .

Cat. No.	Product Name	Target	Research Area

HY-164388

Z-VAD 4 Publications Verification	Caspase Apoptosis Autophagy Necroptosis	Cardiovascular Disease Cancer
Z-VAD is an irreversible, broad-spectrum pan-caspase inhibitor that can inhibit a variety of caspases including caspase-3, -6, -7, -8, -9, etc. (with a weaker inhibitory effect on caspase-2). Z-VAD can block apoptosis signaling pathways, induce autophagy and necrosis in tumor cells, and has anti-angiogenic activity. Z-VAD can enhance the sensitivity of breast cancer and lung cancer cells to radiotherapy in vitro and in vivo, and prolong the growth delay of tumor xenograft models. Z-VAD is well tolerated and is mainly used in research related to cancer radiosensitization and cell death pathway regulation .

HY-P3566

(D-Lys16)-ACTH (1-24) (human, bovine, mouse, ovine, porcine, rabbit, rat)	Biochemical Assay Reagents	Others
(D-Lys16)-ACTH (1-24) (human, bovine, mouse, ovine, porcine, rabbit, rat) is the reaction product with gadolinium tetraazacyclododecanetriacetate derivative. (D-Lys16)-ACTH (1-24) (human, bovine, mouse, ovine, porcine, rabbit, rat) involves in preparation of tetraazacyclododecane macrocycle metal complexes for production of conjugates with biomolecules and for use as NMR contrast agents, radiodiagnostic agents and for radioresearch .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: